- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04882878
A Study of Nipocalimab in Adult Participants With Active Systemic Lupus Erythematosus
April 23, 2024 updated by: Janssen Research & Development, LLC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Nipocalimab in Adult Participants With Active Systemic Lupus Erythematosus
The purpose of this study is to evaluate the efficacy of nipocalimab versus placebo in participants with active systemic lupus erythematosus (SLE).
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
SLE is a complex, immune-mediated inflammatory disorder of unknown etiology that can affect almost any organ system and follows a waxing and waning disease course.
In SLE, the immune system attacks the body cells and tissues and the resulting inflammation and tissue damage can harm the heart, joints, skin, lungs, blood vessels, liver, kidneys, and nervous system.
Nipocalimab is a fully human aglycosylated immunoglobulin (Ig)G1 monoclonal antibody designed to selectively bind, saturate, and block the IgG binding site on the endogenous neonatal fragment crystallizable receptor (FcRn).
Thus, nipocalimab, a FcRn antibody, has potential in treatment of SLE through lowering of pathogenic IgGs and immune complexes.
The study will consist of a Screening Period (less than or equal to [<=] 6 Weeks), double-blind Treatment Period (52 Weeks), and a Follow-up Period (6 Weeks).
Key safety assessments will include adverse events (AEs), serious adverse events (SAEs), adverse events of special interests (AESIs), clinical laboratory tests (hematology, chemistry, urinalysis, and lipid profile) and vital signs.
The total duration of the study is up to 64 weeks.
Study Type
Interventional
Enrollment (Actual)
228
Phase
- Phase 2
Expanded Access
Temporarily not available outside the clinical trial.
See expanded access record.
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Study Contact
- Phone Number: 844-434-4210
- Email: Participate-In-This-Study@its.jnj.com
Study Locations
-
-
-
Buenos Aires, Argentina, C1015ABO
- Centro Médico Reumatológico (OMI)
-
Buenos Aires, Argentina, C1417EYG
- Centro Privado de Medicina Familiar
-
Caba, Argentina, C1406AGA
- ARCIS Salud SRL Aprillus asistencia e investigacion
-
Ciudad De Buenos Aires, Argentina, C1430EGF
- Clínica Adventista Belgrano
-
La Plata, Argentina, B1900
- Hospital Italiano La Plata
-
Mar Del Plata, Argentina, B7600
- Centro de Investigaciones Medicas Mar del Plata
-
Mendoza, Argentina, 5000
- Instituto de Reumatologia - Ir Medical Center S.A.
-
San Miguel De Tucuman, Argentina, T4000AXL
- Centro de Investigaciones Medicas Tucuman
-
-
-
-
-
Plovdiv, Bulgaria, 4000
- Multiprofile Hospital for Active Treatment Plovdiv
-
Sfia, Bulgaria, 1612
- UMHAT St. Ivan Rilski
-
Sofia, Bulgaria, 1431
- Diagnostic-Consultative Center (DCC) Aleksandrovska
-
-
-
-
-
Barranquilla, Colombia, 080001
- Clinica de la Costa SAS
-
Barranquilla, Colombia, 080020
- Centro de Investigacion Medico Asistencial SAS - CIMEDICAL SAS
-
Bogotá, Colombia, 110221
- Centro de Investigación en Reumatología y especialidades médicas S.A.S. - CIREEM S.A.S.
-
Bucaramanga, Colombia
- Servimed S A S
-
Chia, Colombia
- IPS Preventive Care SAS
-
-
-
-
-
Langenau, Germany, 89129
- Praxis Dr. med. Beate Schwarz - Germany
-
Leipzig, Germany, 04103
- Universitaetsklinikum Leipzig
-
-
-
-
-
Budapest, Hungary, 1023
- Betegapolo Irgalmas Rend - Budai Irgalmasrendi Korhaz
-
Gyula, Hungary, 5700
- Bekes Varmegyei Kozponti Korhaz Pandy Kalman Tagkorhaz
-
Zalaegerszeg, Hungary, H-8900
- Belvarosi Egeszseghaz Kft. (Leda-Platan Maganklinika es Sebeszeti Kozpont)
-
-
-
-
-
Chiba, Japan, 260-8712
- National Hospital Organization Chibahigashi National Hospital
-
Fukuoka, Japan, 810 8563
- National Hospital Organization Kyushu Medical Center
-
Ichikawa, Japan, 272-8516
- National Center for Global Health and Medicine, Kohnodai hospital
-
Kanagawa, Japan, 216-8511
- St Marianna University Hospital
-
Kawachi-Nagano, Japan, 586-8521
- National Hospital Organization Osaka Minami Medical Center
-
Nagoya-shi, Japan, 460-0001
- National Hospital Organization Nagoya Medical Center
-
Osaka, Japan, 545 8586
- Osaka Metropolitan University Hospital
-
Sendai shi, Japan, 980 8574
- Tohoku University Hospital
-
Takatsuki, Japan, 569-8686
- Osaka Medical and Pharmaceutical University Hospital
-
Tokyo, Japan, 104 8560
- St. Luke's International Hospital
-
Toyoake, Japan, 470-1192
- Fujita Health University Hospital
-
Tsukuba, Japan, 305 8576
- University of Tsukuba Hospital
-
-
-
-
-
Bydgoszcz, Poland, 85-168
- Szpital Uniwersytecki Nr 2 w Bydgoszczy
-
Bytom, Poland, 41 902
- Nzoz Bif Med
-
Krakow, Poland, 30363
- Centrum Medyczne Plejady
-
Krakow, Poland, 30 002
- Malopolskie Badania Kliniczne Sp z o o
-
Nadarzyn, Poland, 05 830
- NZOZ Lecznica MAK MED S C
-
Poznan, Poland, 61-397
- Prywatna Praktyka Lekarska, Prof. UM dr hab. med. Paweł Hrycaj
-
Poznan, Poland, 61-293
- Twoja Przychodnia Poznanskie Centrum Medyczne
-
Poznan, Poland, 61 113
- AI Centrum Medyczne
-
Rzeszow, Poland, 35-055
- Uniwersytecki Szpital Kliniczny w Rzeszowie
-
Warszawa, Poland, 00874
- MICS Centrum Medyczne Warszawa
-
-
-
-
-
Cape Town, South Africa, 7500
- Panorama Medical Centre
-
George, South Africa, 6529
- Excellentis Clinical trial Consultants
-
Stellenbosch, South Africa, 7600
- Winelands Rheumatology Centre
-
-
-
-
-
Barcelona, Spain, 08035
- Hosp. Univ. Vall D Hebron
-
Madrid, Spain, 28034
- Hosp. Univ. Ramon Y Cajal
-
Pamplona, Spain, 31008
- Hosp. de Navarra
-
Sabadell, Spain, 08208
- Corporacio Sanitari Parc Tauli
-
Zaragoza, Spain, 50009
- Hospital Clinico Universitario Lozano Blesa
-
-
-
-
-
Kaohsiung, Taiwan, 81362
- Kaohsiung Veterans General Hospital
-
Kaohsiung, Taiwan, 88301
- Kaohsiung Chang Gung Memorial Hospital
-
Taichung, Taiwan, 40447
- China Medical University Hospital
-
Taipei, Taiwan, 11031
- Taipei Medical University
-
-
-
-
-
Chernihiv, Ukraine, 14029
- Municipal Non-Profit Enterprise 'Chernihiv Regional Hospital' of Chernihiv Regional Council
-
Kharkiv, Ukraine, 61204
- Municipal Non-Profit Enterprise of Kharkiv Regional Council 'Regional Clinical Hospital'
-
Kyiv, Ukraine, 03049
- Kyiv Railway Clinical Hospital #2 Of Branch 'Health Center' Of The Company 'Ukrainian Railway'
-
Kyiv, Ukraine, 04050
- Medical Center 'Consylium Medical'
-
Kyiv, Ukraine, 03037
- Medbud-Clinic LLC
-
Kyiv, Ukraine, 02091
- Medical Center 'Ok Clinic' of International Institute of Clinical Research LLC
-
Odessa, Ukraine, 65025
- Municipal Non-profit Enterprise 'Odesa Regional Clinical Hospital' Odesa Regional Council
-
Poltava, Ukraine, 36011
- ME Poltava Regional Clinical Hospital named after M.V. Sklifosovsky of Poltava Regional Consuil
-
Vinnytsia, Ukraine, 21018
- MNPE 'Vinnytsia Regional Clinical Hospital named after M.I. Pyrogov of Vinnytsia Regional Council'
-
Zaporizhzhya, Ukraine, 69600
- Medical Center LLC 'Modern Clinic'
-
-
-
-
California
-
Los Alamitos, California, United States, 90720
- Valerius Medical Group & Research Center
-
Rancho Mirage, California, United States, 92270
- Desert Medical Advances
-
Santa Ana, California, United States, 92705
- Wolverine Clinical Trials
-
Thousand Oaks, California, United States, 91360
- Millennium Clinical Trials, LLC
-
-
Florida
-
Brandon, Florida, United States, 33511
- Bay Area Arthritis and Osteoporosis
-
Cooper City, Florida, United States, 33024
- GNP Research
-
Miami, Florida, United States, 33136
- South Coast Research Center
-
Ocoee, Florida, United States, 34761
- Advanced Clinical Research of Orlando
-
Orlando, Florida, United States, 32808
- Omega Research Consultants
-
Ormond Beach, Florida, United States, 32174
- Millennium Research
-
-
Georgia
-
Lawrenceville, Georgia, United States, 30046
- North Georgia Rheumatology, PC
-
Marietta, Georgia, United States, 30060
- Atlanta Research Center for Rheumatology
-
-
Missouri
-
Saint Louis, Missouri, United States, 63131
- West County Rheumatology
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28210
- DJL Clinical Research, PLLC
-
-
Ohio
-
Middleburg Heights, Ohio, United States, 44130
- Paramount Medical Research & Consulting
-
-
Tennessee
-
Memphis, Tennessee, United States, 38119
- Dr. Ramesh Gupta
-
-
Texas
-
Allen, Texas, United States, 75013
- Arthritis and Rheumatology Research Institute
-
Colleyville, Texas, United States, 76034
- Precision Comprehensive Clinical Research Solutions
-
Mesquite, Texas, United States, 75150
- Southwest Rheumatology Research LLC
-
Red Oak, Texas, United States, 75154
- Epic Medical Research
-
-
West Virginia
-
Beckley, West Virginia, United States, 25801
- Rheumatology and Pulmonary Clinic
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Has a clinical diagnosis of systemic lupus erythematosus (SLE) greater than or equal to (>=) 6 months prior to the screening visit and according to Systemic Lupus International Collaborating Clinics (SLICC)-2012 classification criteria: at least 4 criteria fulfilled, with at least 1 clinical criterion and 1 immunologic criterion
- Has at least 1 BILAG (british isles lupus assessment group) A and/or 2 BILAG B scores observed during screening
- Must have at least moderately active SLE, as defined as systemic lupus erythematosus disease activity index 2000 (SLEDAI-2K) score >= 6 at screening visit. Must also have SLEDAI 2K >= 4 for clinical features (that is, SLEDAI-2K score excluding headache and laboratory abnormalities) present at Week 0 prior to randomization
- Has a CLASI (cutaneous lupus erythematosus disease area and severity index) activity score of at least 6 (excluding diffuse non-inflammatory alopecia) or at least 4 joints with pain and signs of inflammation (active joints) at screening or at Week 0, or both
- At least 1 unequivocally positive autoantibody test including antinuclear antibodies (ANA) (>= 1:80) and/or anti-double stranded deoxyribonucleic acid (dsDNA) antibodies (level >= 75 international units/milliliter [IU/mL]) and/or anti-Smith antibodies (>120 Absorbance unit/milliliter [AU/mL]) detected during screening
- Must be receiving 1 or more of the following protocol-permitted, systemic standard-of-care treatments prior to first administration of study intervention at a stable dose: oral glucocorticoids, antimalarial or up to 2 immunomodulatory drugs
Exclusion Criteria:
- Current or history of, severe, progressive, or uncontrolled renal disease, with the exception of active lupus nephritis (LN). Have severe active LN as determined by sponsor (or designee) adjudication. Control of renal disease must be documented with at least 2 measurements of proteinuria or urine protein/creatinine ratio (UPCR) over the 6 months prior to screening
- Has any unstable or progressive manifestation of SLE that is likely to warrant escalation in therapy beyond permitted background medications
- Confirmed or suspected inflammatory diseases that might confound the evaluations of efficacy
- Has a severe infection including opportunistic infections requiring parenteral anti-infectives, and/or hospitalization within 8 weeks prior to screening
- Has received a single B-cell targeting agent within 3 months prior to first administration of study intervention
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Group 1: Placebo
Participants will receive placebo intravenously (IV) every two weeks (q2w) through Week 50 along with standard-of-care treatments (that is, immunomodulators, antimalarial drugs and Glucocorticoids [GCs]).
|
Placebo will be administered intravenously.
Standard-of-care treatment including immunomodulators, antimalarial drugs and GCs will be administered orally.
|
Experimental: Group 2: Nipocalimab Dose 1
Participants will receive nipocalimab dose 1 intravenously (IV) q2w through Week 50 along with standard-of-care treatments (that is, immunomodulators, antimalarial drugs and GCs).
|
Nipocalimab dose 1 and dose 2 will be administered intravenously.
Other Names:
Standard-of-care treatment including immunomodulators, antimalarial drugs and GCs will be administered orally.
|
Experimental: Group 3: Nipocalimab Dose 2
Participants will receive nipocalimab dose 2 intravenously (IV) q2w through Week 50 along with standard-of-care treatments (that is, immunomodulators, antimalarial drugs and GCs).
|
Nipocalimab dose 1 and dose 2 will be administered intravenously.
Other Names:
Standard-of-care treatment including immunomodulators, antimalarial drugs and GCs will be administered orally.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants Achieving an Systemic Lupus Erythematosus (SLE) Responder Index (SRI)-4 Composite Response at Week 24
Time Frame: Week 24
|
SLE SRI-4 composite response is a composite of at least 4-point improvement in SLE Disease Activity Index 2000(SLEDAI-2K), no worsening in British Isles Lupus Assessment Group (BILAG), no worsening in Physician's Global Assessment of Disease Activity score (PGA) and not meeting study treatment failure criteria.
|
Week 24
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Serum Concentration of Nipocalimab Over Time
Time Frame: Up to Week 58
|
Serum concentrations of nipocalimab over time in participants receiving active study intervention will be reported.
|
Up to Week 58
|
Number of Participants with Antibodies to Nipocalimab (Anti-Drug Antibodies [ADAs] and Neutralizing Antibodies [Nabs])
Time Frame: Up to Week 58
|
Number of participants with antibodies to nipocalimab (ADAs and Nabs) in participants receiving active study intervention will be reported.
|
Up to Week 58
|
Percentage of Participants with Baseline Active Mucocutaneous Lupus Manifestations (Cutaneous Lupus Erythematosus Disease Area and Severity Index [CLASI] Activity Score >= 6) Achieving >= 50 Percent (%) Reduction in the CLASI Activity Score at Week 24
Time Frame: Week 24
|
Percentage of participants achieving at least 50% improvement in CLASI Activity Score at Week 24 will be reported in participants with a CLASI Activity Score of 6 or greater at baseline.
Cutaneous lupus disease activity and severity will be measured by the CLASI.
The CLASI is an instrument to assess the disease activity and damage caused to the skin for cutaneous lupus erythematosus participants with or without systemic involvement.
The CLASI consists of 2 scores; the first summarizes the activity of the disease while the second is a measure of the damage caused by the disease.
|
Week 24
|
Percentage of Participants with Baseline Arthritis (with at Least 4 Active Joints at Baseline) Achieving >= 50% Reduction in Active Joints at Week 24
Time Frame: Week 24
|
Percentage of participants with baseline arthritis (with at least 4 active joints at baseline) achieving >= 50% reduction in active joints at Week 24 will be reported.
|
Week 24
|
Percentage of Participants with >= 4 Point Improvement in SLE Disease Activity Index 2000 (SLEDAI-2K) at Week 24
Time Frame: Week 24
|
Percentage of participants achieving at least 4 point improvement in SLEDAI-2K will be reported.
The SLEDAI-2K is an established, validated SLE activity index.
It is based on the presence of 24 features in 9 organ systems and measures disease activity in SLE participants at the time of the visit or in the previous 30 days; the index is weighted according to the feature.
Features are scored by the assessing physician if present at the time of the visit or within the last 30 days, with more severe features having higher scores, and then simply added to determine the total SLEDAI-2K score, which ranges from 0 to 105, with higher scores representing increased disease activity.
|
Week 24
|
Percentage of Participants Achieving the British Isles Lupus Assessment Group (BILAG) Composite Lupus Assessment (BICLA) Response at Week 24
Time Frame: Week 24
|
Percentage of participants achieving BICLA Response (BILAG-2004 disease activity improvement without worsening, and without worsening of SLEDAI-2K or PGA compared to baseline) at Week 24 will be reported.
|
Week 24
|
Time to First Flare Through Week 24
Time Frame: Up to Week 24
|
Time to first flare through Week 24, with flare defined as either 1 or more new BILAG A or 2 or more new BILAG B scores will be reported.
|
Up to Week 24
|
Percentage of Participants Achieving SRI-4 Composite Response at Week 52
Time Frame: Week 52
|
Percentage of participants achieving SRI-4 composite response at Week 52 will be reported.
|
Week 52
|
Percentage of Participants Receiving >= 10 milligram/day (mg/day) Prednisone or Equivalent at Baseline who Achieve Week 6-16 Glucocorticoid (GC) Taper Goal (at Week 16 to <= 7.5 mg/day Prednisone or Equivalent) and Maintain that Reduction Until Week 24
Time Frame: Up to Week 24
|
Percentage of participants receiving >= 10 mg/day prednisone or equivalent at baseline who achieve Week 6-16 GC taper goal (at Week 16 to <= 7.5 mg/day prednisone or equivalent) and maintain that reduction until Week 24 will be reported.
|
Up to Week 24
|
Percentage of Participants with Treatment-emergent Adverse Events (TEAEs) Through Week 58
Time Frame: Up to Week 58
|
An adverse event (AE) is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non investigational) product.
An AE does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.
TEAEs are defined as AEs with onset or worsening on or after date of first dose of study treatment.
|
Up to Week 58
|
Percentage of Participants with Treatment-emergent Serious Adverse Events (SAEs) Through Week 58
Time Frame: Up to Week 58
|
SAE is any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product.
Treatment-emergent SAEs are defined as SAEs with onset or worsening on or after date of first dose of study treatment.
|
Up to Week 58
|
Percentage of Participants with Treatment-emergent Adverse Events of Special interests (AESIs) Through Week 58
Time Frame: Up to Week 58
|
Percentage of participants with treatment-emergent AESIs will be reported.
Treatment-emergent adverse events associated with the following situations are considered as AESIs: infections that are severe or require intravenous anti-infective or operative/invasive intervention, hypoalbuminemia with albumin less than (<) 20 gram/liter (g/L) (<2.0 gram/deciliter [g/dL]).
|
Up to Week 58
|
Percentage of Participants with Treatment-emergent AEs leading to treatment discontinuation Through Week 58
Time Frame: Up to Week 58
|
Percentage of participants with treatment-emergent AEs leading to discontinuation of study intervention will be reported.
|
Up to Week 58
|
Number of Participants with Change from Baseline in Laboratory Parameters Over Time
Time Frame: Up to Week 58
|
Number of participants with change from baseline in laboratory parameters (hematology, chemistry, urinalysis and lipid profile) over time will be reported.
|
Up to Week 58
|
Number of Participants with Change from Baseline in Vital Signs Parameters Over Time
Time Frame: Up to Week 58
|
Number of participants with change from baseline in vital sign parameters (temperature, pulse/heart rate, respiratory rate, and blood pressure) will be reported.
|
Up to Week 58
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Director: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 20, 2021
Primary Completion (Estimated)
May 2, 2024
Study Completion (Estimated)
December 26, 2024
Study Registration Dates
First Submitted
May 7, 2021
First Submitted That Met QC Criteria
May 7, 2021
First Posted (Actual)
May 12, 2021
Study Record Updates
Last Update Posted (Actual)
April 24, 2024
Last Update Submitted That Met QC Criteria
April 23, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CR109011
- 2020-005569-14 (EudraCT Number)
- 80202135SLE2001 (Other Identifier: Janssen Research & Development, LLC)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical
trials/transparency.
As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Systemic Lupus Erythematosus
-
SanofiCompletedCutaneous Lupus Erythematosus-Systemic Lupus ErythematosusJapan
-
Kyowa Kirin Co., Ltd.RecruitingHealthy Volunteers | Systemic Lupus Erythematosus (SLE) | Cutaneous Lupus Erythematosus (CLE)Japan
-
Second Xiangya Hospital of Central South UniversityNational Natural Science Foundation of China; Hunan Provincial Natural Science... and other collaboratorsActive, not recruitingCutaneous Lupus Erythematosus | Systemic Lupus Erythematosus RashChina
-
University Hospital, BrestRecruitingSystemic Lupus Erythematosus (SLE)France
-
Beijing InnoCare Pharma Tech Co., Ltd.RecruitingSystemic Lupus Erythematosus, SLEChina
-
TJ Biopharma Co., Ltd.TerminatedSystemic Lupus Erythematosus (SLE)China
-
AstraZenecaActive, not recruitingActive Systemic Lupus ErythematosusThailand, Korea, Republic of, Philippines, China, Taiwan, Hong Kong
-
Novartis PharmaceuticalsActive, not recruitingSystemic Lupus Erythematosus (SLE)Hungary, Spain, Germany, Israel, Thailand, France, Russian Federation, China, Japan, Taiwan, Korea, Republic of, Poland, Australia, Argentina, Czechia
-
AstraZenecaPRA Health SciencesCompletedActive Systemic Lupus ErythematosusUnited States, France, Germany, Spain, Belgium, Russian Federation, Japan, Korea, Republic of, Argentina, Bulgaria, South Africa, Mexico, Canada, Brazil, Lithuania
-
Novartis PharmaceuticalsNot yet recruitingSystemic Lupus Erythematosus, SLE
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States